# Why AOD-9604 safety findings depend on the formulation

- Article ID: research-033
- Product: AOD-9604 (aod-9604-681, aod-9604-682)
- Canonical page: https://heritagebiolabs.com/research-library/articles/033-why-aod-9604-safety-findings-depend-on-the-formulation
- Product collection: https://heritagebiolabs.com/research-library/products/aod-9604
- Product page: https://heritagebiolabs.com/product/aod-9604-681
- Product page: https://heritagebiolabs.com/product/aod-9604-682
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2013, 2024

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

A short chain of amino acids joined by peptide bonds is a peptide. Peptides can affect cell signals, and their chemical form can influence how they behave during manufacturing and in the body. AOD-9604 is a modified human growth hormone fragment studied in several formulations. The older clinical reports and FDA evaluation raise a practical question about how much can be learned from safety observations on one formulation. [1, 2]

A 2013 paper summarized six controlled human trials. The authors looked for changes associated with full-length growth hormone, such as changes in blood levels of insulin-like growth factor 1 or glucose regulation. They reported no significant change in circulating IGF-1 between treatment and placebo and no detectable antibodies against AOD-9604 in the people selected for antibody testing. The evidence applied to the participants, formulations and periods examined. [2]

When FDA reviewers considered the evidence for compounding, they pointed to important gaps. Much of the clinical evidence was available in summaries with limited details, and they did not identify human studies using the proposed subcutaneous or transdermal forms. They also considered how researchers would identify peptide impurities and whether an altered or aggregated peptide could provoke an immune response. Antibody observations from selected participants receiving one formulation give only a limited view of that question. [1, 2]

The distinction is between a recorded observation and the scope of the claim it can support. Clinical safety data describe the material administered to those participants. Assessing another preparation requires information about what is in it, how it reaches the body, and what investigators observed in studies using that preparation. The FDA briefing considered the free base and acetate as separate bulk substances and recorded that neither was a component of an FDA-approved drug. [1]

## Sources

1. U.S. Food and Drug Administration. FDA Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate). Pharmacy Compounding Advisory Committee briefing (publication 2024-12-04). <https://www.fda.gov/media/183584/download>
2. Heike Stier et al. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism (publication 2013-04). <https://jofem.org/index.php/jofem/article/view/157/194>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 007 - AOD-9604.docx; article 33; content SHA-256 a8404b75b84496cc45cf24e36a41eb96f7412508c534ce33fa282639e7df4c2a.
